Marshall Wace, LLP Biocryst Pharmaceuticals Inc Call Options Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$156 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$153 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$91 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$69.7 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$67.9 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.43B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...